BRISTOL-MYERS SQUIBB CO
BMYNYSETrading Snapshot
- Day Range
- $60.33 β $61.33
- 52-Week Range
- $42.52 β $68.64
- Volume (shares)
- 7,409,824
- Avg Volume (shares)
- β
- Shares Outstanding
- 2.04B
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $48.20B
- Last Q Revenue
- $12.97B
- P/E Ratio
- 13.5
- P/S Ratio
- 2.5x
- EPS (TTM)
- $4.54
- Dividend Yield
- 6.06%
- Dilution (1yr)
- +0.2%
BRISTOL-MYERS SQUIBB CO
BMYAbout BRISTOL-MYERS SQUIBB CO
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

3 Magnificent Dividend Stocks for Risk-Averse Investors
Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.

8,656 Bristol Myers Squibb Company $BMY Shares Sold by Evergreen Capital Management LLC
Evergreen Capital Management LLC reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 20.3% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 34,066

Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression β Here's Why It Matters
It also demonstrated very promising results when evaluated in other solid tumors. The company's involvement in the program is part of a broader effort to develop its burgeoning growth portfolio.

Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Bristol-Myers Squibb heads into Q3 earnings with growth drugs and higher Eliquis guidance offsetting legacy portfolio declines.

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation
Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.